TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38939654

Group type: EXPERIMENTAL
Intervention: Increased left atrial (LA) stiffness
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: LA myopathy with increased LA stiffness and impaired LA mechanics
Number of subjects: 150
Study: 38939657

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 5670

Group type: COMPARATOR
Intervention: Males
Number of subjects: 5670

Group type: EXPERIMENTAL
Intervention: Females under 55 years
Number of subjects: 5670

Group type: EXPERIMENTAL
Intervention: Females over 55 years
Number of subjects: 5670
Study: 38939675

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 9054
Study: 38939799

Group type: EXPERIMENTAL
Intervention: NIPS (noninvasive programmed ventricular stimulation)
Number of subjects: 41
Study: 38939828

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day plus cholecalciferol 800 IU/day (RalD)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Cholecalciferol 800 IU/day (VitD)
Number of subjects: 112
Study: 38940186

Group type: EXPERIMENTAL
Intervention: Quick bedside cTn test by ambulance paramedics using a point-of-care device with the HEART-score
Number of subjects: 0

Group type: COMPARATOR
Intervention: Detailed hospital cTn test by doctors with the HEART-score
Number of subjects: 0
Study: 38940282

Group type: EXPERIMENTAL
Intervention: Apalutamide 240 mg/day
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1052
Study: 38940297

Group type: EXPERIMENTAL
Intervention: Integrated valve technology
Number of subjects: 2913

Group type: EXPERIMENTAL
Intervention: Anti-thrombogenic surface modification
Number of subjects: 2913

Group type: EXPERIMENTAL
Intervention: Antimicrobial impregnation
Number of subjects: 2913
Study: 38940373

Group type: EXPERIMENTAL
Intervention: Oregovomab plus non-platinum-based chemotherapy (pegylated liposomal doxorubicin or paclitaxel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-platinum-based chemotherapy (pegylated liposomal doxorubicin or paclitaxel)
Number of subjects: 0
Study: 38940374

Group type: EXPERIMENTAL
Intervention: Subjective Visual Vertical (SVV)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Subjective Haptic Vertical (SHV)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Starting positions
Number of subjects: 60
Study: 38940435

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38940494

Group type: EXPERIMENTAL
Intervention: Educational programme for healthcare professionals (bespoke interactive online learning and reinforcement activities)
Number of subjects: 1732

Group type: EXPERIMENTAL
Intervention: Educational programme for healthcare professionals
Number of subjects: 1732

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants
Number of subjects: 1732

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug therapy
Number of subjects: 1732

Group type: EXPERIMENTAL
Intervention: Scheduled for future cardioversion or ablation
Number of subjects: 1732
Study: 38940656

Group type: EXPERIMENTAL
Intervention: Phosphorylated plasma Tau217 ratio (pTau217R)
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: Combination of pTau217R and plasma Aβ42/Aβ40
Number of subjects: 904

Group type: COMPARATOR
Intervention: Aβ42/Aβ40 alone
Number of subjects: 904
Study: 38940695

Group type: EXPERIMENTAL
Intervention: Surgical management (reconstruction)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Non-surgical management (rehabilitation)
Number of subjects: 316
Study: 38940733

Group type: EXPERIMENTAL
Intervention: Photobiomodulation Treatment with a Home-Use Device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38940865

Group type: EXPERIMENTAL
Intervention: JN.1 infection
Number of subjects: 182

Group type: COMPARATOR
Intervention: XBB infection
Number of subjects: 182
Study: 38940898

Group type: EXPERIMENTAL
Intervention: GACMS
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: RRM
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Calculated breast cancer risk
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Elevated breast cancer risk
Number of subjects: 25
Study: 38940981

Group type: EXPERIMENTAL
Intervention: Ovarian function recovery (OFR) in patients with CIOFF receiving anastrozole treatment.
Number of subjects: 656
Study: 38941062

Group type: EXPERIMENTAL
Intervention: Metal-on-polyethylene (MoP) arthroplasty implants
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (deceased subjects without prostheses)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: MoP arthroplasty implants
Number of subjects: 25
Study: 38941068

Group type: EXPERIMENTAL
Intervention: VOWST oral spores (VOS)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 349
Study: 38941132

Group type: EXPERIMENTAL
Intervention: 6-minute stepper test (6MST) conducted under direct supervision
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 6-minute stepper test (6MST) conducted under remote supervision
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Concurrent validity of 6MST compared to CPET and 6MWT
Number of subjects: 82

Group type: COMPARATOR
Intervention: 6-minute walk test (6MWT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Maximal cardiopulmonary exercise testing (CPET)
Number of subjects: 82
Study: 38941145

Group type: EXPERIMENTAL
Intervention: Web-based PA intervention (WI) program
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Web-based PA intervention (WI) program with Just-in-Time Adaptive Intervention (WI+JITAI)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group (WI)
Number of subjects: 196
Study: 38941148

Group type: EXPERIMENTAL
Intervention: Patient portal intervention
Number of subjects: 433

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 433
Study: 38941376

Group type: EXPERIMENTAL
Intervention: Serum Raftlin levels in axSpA patients
Number of subjects: 120

Group type: COMPARATOR
Intervention: Serum Raftlin levels in PsA patients
Number of subjects: 120

Group type: COMPARATOR
Intervention: Serum Raftlin levels in control group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Raftlin level ≥ 6.31 ng/mL
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Correlation of Raftlin levels with disease activity measures in axSpA patients
Number of subjects: 120
Study: 38941511

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 11040
Study: 38941593

Group type: EXPERIMENTAL
Intervention: KAD patients with HIV
Number of subjects: 0

Group type: COMPARATOR
Intervention: KICS and MCD
Number of subjects: 0

Group type: COMPARATOR
Intervention: PEL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KAD patients
Number of subjects: 0
Study: 38941599

Group type: EXPERIMENTAL
Intervention: Syalox 300 Plus (high-molecular-weight hyaluronic acid) administered orally for 8 weeks.
Number of subjects: 8
Study: 38941601

Group type: EXPERIMENTAL
Intervention: MI-BP intervention
Number of subjects: 162

Group type: COMPARATOR
Intervention: Enhanced usual care control
Number of subjects: 162
Study: 38941963

Group type: EXPERIMENTAL
Intervention: SLN ultrastaging
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Examination of four levels from paraffin blocks
Number of subjects: 733
Study: 38942046

Group type: EXPERIMENTAL
Intervention: Nivolumab plus surgery
Number of subjects: 819

Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 819
Study: 38942047

Group type: EXPERIMENTAL
Intervention: Namilumab 150 mg subcutaneously at weeks 0, 2, 6, and 10
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Namilumab 150 mg
Number of subjects: 42
Study: 38942114

Group type: EXPERIMENTAL
Intervention: Elevated Lp(a) (≥150 nmol/L)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Normal Lp(a) and OxPL concentrations
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Addition of OxPL-apoB and OxPL-apo(a) to Lp(a)
Number of subjects: 446
Study: 38942209

Group type: COMPARATOR
Intervention: Cariprazine 1.5 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cariprazine 3-12 mg/d
Number of subjects: 0
Study: 38942591

Group type: EXPERIMENTAL
Intervention: MIST continuation group (n=25)
Number of subjects: 52

Group type: COMPARATOR
Intervention: MIST discontinuation group (n=27)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Patients with anti-dsDNA IgE levels above vs below 1.9 arbitrary units
Number of subjects: 52
Study: 38942592

Group type: EXPERIMENTAL
Intervention: Nipocalimab (15 mg/kg intravenously every 2 weeks)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Nipocalimab
Number of subjects: 53
Study: 38942601

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) exposure in early pregnancy
Number of subjects: 100
Study: 38942693

Group type: EXPERIMENTAL
Intervention: Vicriviroc 150 mg orally once daily plus pembrolizumab 200 mg intravenously every 3 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vicriviroc 250 mg orally once daily plus pembrolizumab 200 mg intravenously every 3 weeks
Number of subjects: 40
Study: 38942993

Group type: EXPERIMENTAL
Intervention: Finotonlimab plus cisplatin plus 5-fluorouracil (C5F)
Number of subjects: 370
Study: 38942994

Group type: EXPERIMENTAL
Intervention: AAV gene therapy (AP4M1 gene) administered intrathecally
Number of subjects: 1
Study: 38942995

Group type: EXPERIMENTAL
Intervention: Cabozantinib and nivolumab with CBM588
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cabozantinib and nivolumab without CBM588 (control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cabozantinib and nivolumab with or without CBM588
Number of subjects: 30
Study: 38943014

Group type: EXPERIMENTAL
Intervention: Standardized SMAs (set content delivered by a health educator)
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Patient-driven SMAs (patient-selected topic order delivered by health educators, BHPs, and peer mentors)
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Standardized SMAs
Number of subjects: 1060
Study: 38943053

Group type: EXPERIMENTAL
Intervention: Educational program combining three nutritional workshops and 12 weekly physical activity sessions.
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Regular participation in the program.
Number of subjects: 187

Group type: COMPARATOR
Intervention: Non-participants in the program.
Number of subjects: 187
Study: 38943063

Group type: EXPERIMENTAL
Intervention: Identification of CEBA profiles through neuropsychological assessment tests and questionnaires.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Qualitative evaluation of treatment suitability for CEBA profiles in a small group of PwMS.
Number of subjects: 300
Study: 38943136

Group type: EXPERIMENTAL
Intervention: Maternal dental anxiety (assessed using the Modified Dental Anxiety Scale - MDAS)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Children's dental anxiety (assessed using the Venham Picture Test - VPT)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Maternal dental anxiety
Number of subjects: 305

Group type: COMPARATOR
Intervention: Children aged 4-7
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Children aged 8-12
Number of subjects: 305
Study: 38943155

Group type: COMPARATOR
Intervention: α-cypermethrin only LLIN
Number of subjects: 0

Group type: COMPARATOR
Intervention: pyriproxyfen and α-cypermethrin (PPF-PY) LLIN
Number of subjects: 0

Group type: COMPARATOR
Intervention: chlorfenapyr and α-cypermethrin (chlorfenapyr-PY) LLIN
Number of subjects: 0

Group type: COMPARATOR
Intervention: piperonyl butoxide and permethrin (PBO-PY) LLIN
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Good condition nets vs too-torn nets
Number of subjects: 0

Group type: COMPARATOR
Intervention: too-torn PBO-PY LLIN vs intact PY-only LLIN
Number of subjects: 0

Group type: COMPARATOR
Intervention: too-torn chlorfenapyr-PY LLIN vs intact PY-only LLIN
Number of subjects: 0

Group type: COMPARATOR
Intervention: intact chlorfenapyr-PY LLIN vs intact PY LLIN (Year 2)
Number of subjects: 0
Study: 38943163

Group type: EXPERIMENTAL
Intervention: Guideline recommendations for pre-operative examinations
Number of subjects: 2003

Group type: EXPERIMENTAL
Intervention: ASA score
Number of subjects: 2003

Group type: EXPERIMENTAL
Intervention: Surgery risk level
Number of subjects: 2003

Group type: EXPERIMENTAL
Intervention: Technical and laboratory tests
Number of subjects: 2003
Study: 38943169

Group type: EXPERIMENTAL
Intervention: BeSmooth BMS (Bentley Innomed GmbH)
Number of subjects: 98

Group type: COMPARATOR
Intervention: BeGraft CS (Bentley Innomed GmbH)
Number of subjects: 98
Study: 38943176

Group type: EXPERIMENTAL
Intervention: HOW R U? intervention delivered by intergenerational volunteers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard same-generation peer support HOW R U? intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Common wait-list control group
Number of subjects: 0
Study: 38943178

Group type: EXPERIMENTAL
Intervention: Multicomponent supervised tele-rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Home-based self-rehabilitation
Number of subjects: 0
Study: 38943179

Group type: COMPARATOR
Intervention: Routine supplementation (400 IU/day with established feedings)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Increased supplementation (800 IU/day with any feedings)
Number of subjects: 180
Study: 38943192

Group type: EXPERIMENTAL
Intervention: Vilobelimab (C5a inhibitor)
Number of subjects: 368
Study: 38943197

Group type: EXPERIMENTAL
Intervention: 12 sessions of process-based working memory training (experimental group)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Active control group (multi-domain training)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Passive control group
Number of subjects: 94
Study: 38943203

Group type: EXPERIMENTAL
Intervention: miLab™ (automated mode)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: miLab™ (corrected mode)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: miLab™
Number of subjects: 190
Study: 38943204

Group type: EXPERIMENTAL
Intervention: Clinically matched incremental hemodialysis (CMIHD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional hemodialysis (CHD)
Number of subjects: 0
Study: 38943294

Group type: EXPERIMENTAL
Intervention: Short messages informing relatives during surgery (preparations for surgery have begun, surgery has started, surgery is ongoing, surgery is completed)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no short messages)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Short messages informing relatives during surgery
Number of subjects: 84
Study: 38943664

Group type: EXPERIMENTAL
Intervention: Sapanisertib (5 mg daily)
Number of subjects: 46
Study: 38943710

Group type: EXPERIMENTAL
Intervention: Lactate-to-albumin ratio (LAR)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Albumin levels
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Total cholesterol levels
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: HDL cholesterol levels
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: LAR, albumin, total cholesterol, and HDL-cholesterol levels
Number of subjects: 219
Study: 38943838

Group type: EXPERIMENTAL
Intervention: Music during ROP examination
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 28
Study: 38943928

Group type: EXPERIMENTAL
Intervention: Luvadaxistat 50 mg
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Luvadaxistat 125 mg
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Luvadaxistat 500 mg
Number of subjects: 256
Study: 38944045

Group type: EXPERIMENTAL
Intervention: Natural cycle endometrial preparation
Number of subjects: 1428

Group type: EXPERIMENTAL
Intervention: Modified natural cycle endometrial preparation
Number of subjects: 1428

Group type: COMPARATOR
Intervention: Artificial cycle endometrial preparation
Number of subjects: 1428
Study: 38944147

Group type: EXPERIMENTAL
Intervention: Plasma YKL-40 levels in drinkers (highest quartile)
Number of subjects: 3267

Group type: COMPARATOR
Intervention: Plasma YKL-40 levels in nondrinkers (lowest quartile)
Number of subjects: 3267

Group type: EXPERIMENTAL
Intervention: Log-transformed YKL-40 increase for light drinkers
Number of subjects: 3267

Group type: EXPERIMENTAL
Intervention: Log-transformed YKL-40 increase for heavy drinkers
Number of subjects: 3267
Study: 38944418

Group type: EXPERIMENTAL
Intervention: AF burden >0.2%
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: AF episode duration >1 hour
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Intermediate AF burden (0.2-1.9%)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Number of AF episodes >147
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Higher AF burden and longer episode duration
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Higher number of episodes
Number of subjects: 417
Study: 38944806

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) and androgen deprivation therapy (ADT) for at least 24 months
Number of subjects: 81
Study: 38945140

Group type: EXPERIMENTAL
Intervention: Intensive treatment targeting systolic blood pressure of less than 120 mm Hg
Number of subjects: 11255

Group type: COMPARATOR
Intervention: Standard treatment targeting systolic blood pressure of less than 140 mm Hg
Number of subjects: 11255

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 11255

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 11255
Study: 38945791

Group type: EXPERIMENTAL
Intervention: Nivolumab, doxorubicin, vinblastine, and dacarbazine (N-AVD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (BV-AVD)
Number of subjects: 0
Study: 38945800

Group type: EXPERIMENTAL
Intervention: Furmonertinib combined with carboplatin and pemetrexed for 4 cycles, then furmonertinib and pemetrexed as maintenance therapy (Arm B2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Furmonertinib combined with carboplatin and pemetrexed for 4 cycles, then furmonertinib and pemetrexed as maintenance therapy plus bevacizumab (Arm B3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Furmonertinib monotherapy (Arm B1)
Number of subjects: 0
Study: 38946010

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure (BP) control
Number of subjects: 8016

Group type: EXPERIMENTAL
Intervention: Achieving a BP target of < 120/80 mmHg
Number of subjects: 8016
Study: 38946384

Group type: EXPERIMENTAL
Intervention: Mini-fluid challenge (MFC) with 100 mL of crystalloids
Number of subjects: 33

Group type: COMPARATOR
Intervention: Short-time low positive end-expiratory pressure (PEEP) challenge (SLPC) with an additional 5 cmH2O PEEP
Number of subjects: 33
Study: 38946484

Group type: EXPERIMENTAL
Intervention: ABBV-184 (0.07 ug/kg initially, with 2- to 3-fold dose increases)
Number of subjects: 15
Study: 38946973

Group type: EXPERIMENTAL
Intervention: JAK inhibitor tofacitinib
Number of subjects: 10
Study: 38947035

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 633

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 633
Study: 38947064

Group type: EXPERIMENTAL
Intervention: 12 hours of therapeutic cooling
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: 24 hours of therapeutic cooling
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: 48 hours of therapeutic cooling
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Shorter and longer duration arms (to be opened during the trial)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Therapeutic hypothermia
Number of subjects: 1800
Study: 38947088

Group type: EXPERIMENTAL
Intervention: MRSA nasal swab PCR testing in addition to usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study: 38947093

Group type: EXPERIMENTAL
Intervention: Chest-X-ray (CXR) with computer-aided detection (CAD) algorithms
Number of subjects: 1392

Group type: EXPERIMENTAL
Intervention: Xpert TB Host Response (HR) testing
Number of subjects: 1392

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) testing
Number of subjects: 1392

Group type: EXPERIMENTAL
Intervention: Xpert HR-CAD4TB (sequential negative screening)
Number of subjects: 1392

Group type: EXPERIMENTAL
Intervention: CRP-CAD4TB (sequential negative screening)
Number of subjects: 1392

Group type: EXPERIMENTAL
Intervention: Xpert HR-CAD4TB (sequential positive screening)
Number of subjects: 1392
Study: 38947097

Group type: EXPERIMENTAL
Intervention: Cold milk feeding
Number of subjects: 26

Group type: COMPARATOR
Intervention: Room temperature milk feeding
Number of subjects: 26
Study: 38947220

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing (CPET)
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Oxygen uptake at peak exercise (VO2)
Number of subjects: 611
Study: 38947228

Group type: EXPERIMENTAL
Intervention: CPX-351 (liposomal daunorubicin and cytarabine) administered at 135 units/m
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard anthracyclines (in ongoing randomized trial)
Number of subjects: 38
Study: 38947304

Group type: EXPERIMENTAL
Intervention: BLS simulation training using AHA-BLS-2020 guidelines
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 102
Study: 38947323

Group type: EXPERIMENTAL
Intervention: Primary cytoreductive surgery
Number of subjects: 22

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Laparoscopy scoring
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cytoreductive surgery
Number of subjects: 22
Study: 38947738

Group type: EXPERIMENTAL
Intervention: Search engine ads
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paid advertising within a national testing company
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paid advertising within a regional testing company
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electronic health record messages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Word of mouth
Number of subjects: 0
Study: 38948108

Group type: EXPERIMENTAL
Intervention: High prenatal DHA supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low prenatal DHA supplementation
Number of subjects: 0